Oral anticoagulation continuation vs. discontinuation after catheter-ablation of paroxysmal atrial fibrillation - incidence of cerebral insults and severe hemorrhagic complications

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Ms Lena Pracht

German Heart Center Muenchen Technical University of Munich, Munich (Germany)

10 More presentations in this session

Presentation thumbnail

Antithrombotic management in patients with atrial fibrillation and acute coronary syndromes

Associate Professor B. Hudzik (Zabrze, PL)

Abstract Slides

Presentation thumbnail

Advantage of novel oral anticoagulants compared to vitamin-K antagonist in atrial fibrillation. Data from real world.

Doctor G. Simonyi (Budapest, HU)

Abstract Slides

Presentation thumbnail

Prior antithrombotic therapy: a snapshot of 17,769 patients from the global edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation programme (global ETNA-AF)

Professor R. De Caterina (Pisa, IT)

Abstract Slides

Presentation thumbnail

A new score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs

Doctor O. Rutherford (Sarpsborg, NO)

Abstract Slides

Presentation thumbnail

Difference of efficacy and safety of left atrial appendage closure using watchman between patients aged less than 75 to more than 75 years

Doctor J. Yu (Koblenz, DE)

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation - Stroke prevention 2

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

Treatment strategies for atrial fibrillation in heart failure - discussion

Congress Presentation

Interactive discussion and Q&A

Congress Presentation

Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources